Anti-LRRC15 ADC Antibody for Epitope-Specific Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for antibodies that effectively target LRRC15 for cancer treatment, as existing anti-LRRC15 antibody-drug conjugates have not been adequately developed, and there is a lack of approved anticancer agents targeting this protein.
Innovation Solution
Development of a novel anti-LRRC15 antibody that specifically binds to specific epitopes in the LRRC15 protein, particularly in regions spanning amino acid residues 22 to 315, and its conjugation with a pyrrolobenzodiazepine (PBD) derivative to form an antibody-drug conjugate, exhibiting strong antitumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-LRRC15 antibody-drug conjugates are used, then cancer treatment is provided, but the therapeutic efficacy is insufficient and no approved anticancer agents targeting LRRC15 are available
Solution Approach 1:
The invention segments the antibody development process by identifying and targeting specific epitope regions within LRRC15 (amino acid residues 22-315), creating specialized antibodies that bind to distinct regions. This segmentation allows for optimized therapeutic efficacy by selecting the most effective epitope-specific antibody for drug conjugation.
Solution Approach 2:
The invention changes key parameters of the antibody-drug conjugate by using pyrrolobenzodiazepine (PBD) derivative conjugation instead of conventional cytotoxic agents like MMAE. This parameter change in the drug component provides enhanced antitumor activity and distinguishes the new conjugate from existing approved agents.
2Measurement precision
If a novel anti-LRRC15 antibody is developed to specifically bind to specific epitopes, then binding specificity is improved, but development complexity and time increase
Solution Approach 1:
The invention applies local quality by directing antibody binding to specific local regions (epitopes) within the LRRC15 protein structure. By focusing on particular amino acid residue regions (22-315), the antibody achieves high binding specificity to critical functional domains while simplifying the overall development approach through targeted region selection.
3Reliability
If an antibody-drug conjugate with strong antitumor activity is created, then therapeutic potential is enhanced, but manufacturing and conjugation complexity increases
Solution Approach 1:
The invention creates a composite material system by conjugating the anti-LRRC15 antibody with pyrrolobenzodiazepine (PBD) derivative drugs. This composite structure combines the target-specific binding capability of the antibody with the potent antitumor activity of PBD, achieving enhanced therapeutic effect while the modular composite design facilitates standardized manufacturing processes.
Data Source
Figure 1-1~1-2
Figure 2-1
Figure 2-2
AI summary
An object of the present invention is to provide a novel LRRC15 antibody or an antigen-binding fragment thereof that can be advantageously used in various therapeutic modalities, especially in antibody-drug conjugates (ADC), for example. The present invention provides an antibody that specifically binds to a novel epitope in LRRC15, for example.